Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	99402
Country	Peru

Received	2024-07-22 00:26
Peer-Review Started	2024-07-22 00:26
To Make the First Decision
Return for Revision	2024-08-17 19:16
Revised	2024-08-31 10:45
Second Decision	2024-09-19 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-19 08:17
Articles in Press	2024-09-19 08:17
Publication Fee Transferred	2024-09-25 14:34
Edit the Manuscript by Language Editor	2024-10-11 10:52
Typeset the Manuscript	2024-10-16 03:17
Publish the Manuscript Online	2024-11-12 12:23

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center
Manuscript Source	Unsolicited Manuscript
All Author List	Wagner Eduardo Cruz-Diaz, Victor Paitan, Jersinho Medina, Raymundo Flores, Juan Haro-Varas, Raul Mantilla and Victor Castro-Oliden
Funding Agency and Grant Number
Corresponding Author	Wagner Eduardo Cruz-Diaz, MD, Staff Physician, Department of Oncology, Instituto Nacional de Enfermedades Neoplasicas, Avenue Angamos Este 2520, Surquillo, Lima 15038, Peru. wagner.cruz@upch.pe
Key Words	Well-differentiated; Gastroenteropancreatic neuroendocrine tumors; Capecitabine; Temozolomide; Retrospective study; Treatment; Chemotherapy
Core Tip	In this study, patients diagnosed with advanced gastroenteropancreatic neuroendocrine tumors who were treated with the temozolomide and capecitabine regimen exhibited a median overall survival of 49 months, with 42% surviving at 60 months. The regimen was well-tolerated, and most patients experienced stable disease. These findings suggest that this treatment could be viable in settings where standard therapies are unavailable or inaccessible, though further prospective studies are needed for confirmation.
Publish Date	2024-11-12 12:23
Citation	<p>Cruz-Diaz WE, Paitan V, Medina J, Flores R, Haro-Varas J, Mantilla R, Castro-Oliden V. Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center. <i>World J Gastrointest Oncol</i> 2024; 16(12): 4675-4684</p>
URL	https://www.wjgnet.com/1948-5204/full/v16/i12/4675.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i12.4675

Full Article (PDF)	WJGO-16-4675-with-cover.pdf
Manuscript File	99402_Auto_Edited_014039.docx
Answering Reviewers	99402-answering-reviewers.pdf
Audio Core Tip	99402-audio.mp3
Biostatistics Review Certificate	99402-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	99402-conflict-of-interest-statement.pdf
Copyright License Agreement	99402-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	99402-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	99402-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	99402-non-native-speakers.pdf
Peer-review Report	99402-peer-reviews.pdf
Scientific Misconduct Check	99402-scientific-misconduct-check.png
Scientific Editor Work List	99402-scientific-editor-work-list.pdf
CrossCheck Report	99402-crosscheck-report.png
CrossCheck Report	99402-crosscheck-report.pdf